Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors RECK and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 12/January/2017, 11.11 pm

Lifespan extension therapy: Coenzyme Q10 may increase life span via up-regulation of its target gene BubR1, 12/January/2017, 12.39 am
January 11, 2018
Vitamin-based combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing Vitamin-B12  and Omega-3-fatty acids (VB12O3FA)  augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 12/January/2017, 11.22 pm
January 12, 2018
Show all

From Significance of the study to Public health relevance: 

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

This study suggests, for the first time, that  the anti-hypertensive drug Torasemide, by regulating the expression of its target genes, it may increase the expression of tumor/metastatic suppressors RECK and CADM1 (fig. 1).

 

Thereby, it may: (a) inhibit cell cycle progression; and (b) suppress migration, invasion and metastasis of cancer cells.   

Given the mechanism of action of Torasemide, it may be an ideal anti-metastatic agent to  (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy.

Taken together, this study suggests that oncologists may consider treating terminally ill metastatic cancer patients with Torasemide, to stall the progression of advanced metastatic cancers.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D

Amount: $10#

Undisclosed mechanistic information: How Torasemide increases the expression of  tumor/metastatic suppressors RECK and CADM1

Fig1. Mechanistic insights into how the anti-hypertensive medication Torsemide functions as an anti-metastasis agent. Torasemide increases the expression of tumor/metastatic suppressors RECK and CADM1 via up regulation of its target genes.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

CitationBoominathan, L., Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors RECK and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 12/January/2017, 11.11 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.